The New Age of Longevity Peptides

The short version

New Age Peptide is a reading desk built around three compounds that keep coming up in the same conversation about aging well: NAD+ (nicotinamide adenine dinucleotide), MOTS-c, and Epitalon. None of them are approved medicines, and none of them are marketed here as one. What they share is an angle on the same underlying question — as cells get older, why do they get worse at making energy, repairing damage, and keeping time, and can a molecule nudge any of that back?

NAD+ is a coenzyme every cell needs to burn fuel and fix DNA, and its tissue levels reliably fall with age. MOTS-c is a tiny peptide encoded inside the mitochondria themselves that appears to sense metabolic stress and push cells back toward balance. Epitalon is a synthetic four-amino-acid peptide, derived from the amino-acid pattern of a bovine pineal extract, studied for its effects on telomere length and the body's internal clock.

This site walks through what the published research actually found for each one — not the marketing pitch, not the forum thread — with a citation behind every specific number. Nothing here is for sale, no dose is recommended to any person, and nothing here is medical advice.

The new age of longevity peptides

The three compounds on this desk are grouped under one frame: the new age of longevity peptides — NAD+, mitochondrial and pineal research. NAD+ leads the set because it has the deepest evidence base and the clearest mechanistic story: it is the cell's central redox carrier, shuttled through glycolysis and oxidative phosphorylation to make ATP, and also a substrate consumed by the sirtuins, PARPs and CD38 enzymes that govern DNA repair, gene regulation and inflammation. Tissue NAD+ decline with age is one of the more consistently observed findings in the field, partly because the NAD-consuming enzyme CD38 rises as organisms get older ^[4].

MOTS-c widens the frame to the mitochondrion itself. It is one of a small class of mitochondrial-derived peptides — molecules encoded not in nuclear DNA but inside the mitochondrial genome — that appear to act as stress sensors, communicating a cell's energy state back to the nucleus ^[12]. Epitalon widens the frame again, to the pineal gland and the circadian axis: it is studied for a proposed effect on telomerase and on melatonin synthesis, tying cellular aging to the body's sleep-wake clock ^[13][15]. Read together, the three sketch a rough map of where longevity research is currently looking — coenzyme depletion, mitochondrial signaling, and neuroendocrine aging — without claiming any of the three has closed the case.

What are research peptides?

Peptides are short chains of amino acids — the same building blocks that make up proteins, just far fewer of them strung together. MOTS-c (16 amino acids) and Epitalon (4 amino acids) are true peptides in that sense. NAD+ is not, technically: it is a dinucleotide coenzyme, a molecule built from two nucleotides joined by phosphate groups, and it is usually sold and studied as a small-molecule metabolite or supplement rather than a peptide. It sits on this desk because it belongs to the same longevity-research conversation, not because it shares MOTS-c and Epitalon's chemistry.

All three are studied compounds, not consumer products with established safety records. MOTS-c is sold only as a research chemical, labeled not for human consumption. Epitalon is classified the same way in the US, EU and UK. NAD+ and its precursors occupy a different, messier category — legally sold as dietary supplements, with an unsettled regulatory picture for at least one precursor (NMN) and a documented contamination recall for at least one compounded injectable form. This site reports what the literature found in each case; it does not recommend using, sourcing, or dosing any of them.

How these three fit together

NAD+ has the most mature human evidence of the three — multiple randomized, placebo-controlled trials of its precursors NMN and NR have shown dose-dependent increases in blood NAD+ with a generally favorable safety record ^[2][5], even as a major 2025 review concluded that translation to hard clinical outcomes remains limited and under-studied ^[1].

MOTS-c sits earlier on the evidence curve. Its strongest human data point is an observational association between circulating MOTS-c and mortality risk in a hemodialysis cohort ^[9] — real, but a long way from a clinical trial of exogenous MOTS-c in healthy adults, which does not yet exist. Everything about exercise capacity and metabolic effects comes from mouse studies ^[8][11].

Epitalon carries the deepest history and the thinnest independent replication. Its core telomerase claim traces to in-vitro work from a single research group going back to 2003 ^[16], with a 2025 study finally extending that result — and complicating it, in cancer cell lines — in more current cell models ^[14]. Its most-cited human data, an elderly-cohort mortality study, was observational rather than randomized ^[17].

Use the comparison page to see all three side by side on mechanism, evidence maturity, and regulatory status.